Ticker brief
RGNX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
29
authors 14d
20
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-01 · now +0.00 (−1 bearish … +1 bullish)
Who spoke20
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BioStocks | C | -0.39 | 3 | +0.45 |
| @BiopharmIQ | B | · | 3 | +0.32 |
| @AponiaAnalytics | B | +0.89 | 3 | +0.28 |
| @adamfeuerstein | A | +1.05 | 2 | +0.42 |
| @Greatstockpix | C | -0.61 | 2 | +0.00 |
| @OzmosiHealth | C | · | 2 | +0.33 |
| @InvestmentGuru_ | C | +0.03 | 1 | +0.55 |
| @WSJ | A | +0.51 | 1 | +0.50 |
| @PersimmonTI | A | -0.32 | 1 | +0.50 |
| @OMillionaires | C | -1.10 | 1 | +0.50 |
| @CryptoMilox | C | -0.69 | 1 | +0.50 |
| @biggercapital | C | +1.10 | 1 | +0.15 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @semodough | C | -0.75 | 1 | +0.45 |
| @FierceBiotech | A | -0.09 | 1 | +0.40 |
| @fwpharma | B | +0.22 | 1 | +0.40 |
| @CrweWorld | C | · | 1 | +0.40 |
| @Brad_E_Schulz | C | · | 1 | +0.10 |
| @MinervaCap | C | -1.28 | 1 | +0.00 |
| @Quantumup1 | C | -1.95 | 1 | +0.00 |
Recent signals29of 29 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @AponiaAnalytics | +0.00 | REGENXBIO amended Schedule TO only to add employee reminder, no term changes. | · | tweet ↗ |
| 2026-06-30 | @Quantumup1 | +0.00 | BTIG raises MNPR PT to $117 from $104 and reiterates Buy on regulatory outlook. | · | tweet ↗ |
| 2026-06-29 | @MinervaCap | +0.00 | Daily watchlist with tickers but no concrete entry intent. | · | tweet ↗ |
| 2026-06-29 | @Brad_E_Schulz | +0.10 | Sector performance table with percent moves and breadth counts. | · | tweet ↗ |
| 2026-06-29 | @AponiaAnalytics | +0.40 | REGENXBIO dosed first patient, triggering a $100M AbbVie milestone. | · | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.25 | Biotech stock news list with percent moves and catalysts at open. | · | tweet ↗ |
| 2026-06-29 | @OzmosiHealth | +0.35 | REGENXBIO announces first patient dosed and $100M milestone. | · | tweet ↗ |
| 2026-06-24 | @BiopharmIQ | +0.35 | Biotech stock moves list with key percentage moves and associated news headlines. | · | tweet ↗ |
| 2026-06-24 | @OzmosiHealth | +0.30 | REGENXBIO completes dosing in confirmatory RGX-202 study and supports planned Q3 2026 BLA. | · | tweet ↗ |
| 2026-06-24 | @adamfeuerstein | +0.35 | Regenxbio will submit Duchenne gene therapy for FDA approval. | · | tweet ↗ |
| 2026-06-24 | @CrweWorld | +0.40 | REGENXBIO completes confirmatory dosing and supports planned BLA submission in Q3 2026. | · | tweet ↗ |
| 2026-06-24 | @AponiaAnalytics | +0.45 | RGX-202 confirmatory dosing completed ahead of schedule, enabling Q3 2026 BLA. | · | tweet ↗ |
| 2026-06-24 | @BioStocks | +0.35 | RGNX completes dosing in confirmatory DMD study early, with BLA expected in Q3. | · | tweet ↗ |
| 2026-06-22 | @fwpharma | +0.40 | FDA rethink opens door for Regenxbio gene therapy comeback. | · | tweet ↗ |
| 2026-06-22 | @Greatstockpix | +0.00 | Day trading watch list names tickers without explicit entry intent. | · | tweet ↗ |
| 2026-06-22 | @FierceBiotech | +0.40 | FDA to reconsider Regenxbio gene therapy. | · | tweet ↗ |
| 2026-06-22 | @BiopharmIQ | +0.35 | Biotech stock moves list with percentage changes and associated clinical/regulatory headlines. | · | tweet ↗ |
| 2026-06-22 | @semodough | +0.45 | Baird sees favorable readthrough and raises RGNX PT to $32. | · | tweet ↗ |
| 2026-06-22 | @OpenOutcrier | +0.50 | FDA gives Regenxbio rare-disease drug another shot. | · | tweet ↗ |
| 2026-06-22 | @biggercapital | +0.15 | Says CLPT partner ecosystem creates a Blue Ocean opportunity. | · | tweet ↗ |
| 2026-06-22 | @Greatstockpix | +0.00 | Gapper watch list without explicit entry intent. | · | tweet ↗ |
| 2026-06-22 | @CryptoMilox | +0.50 | FDA confirmed no new studies needed and existing data sufficient for accelerated approval path. | · | tweet ↗ |
| 2026-06-22 | @OMillionaires | +0.50 | FDA will reverse rejection of Regenxbio rare-disease drug, per company. | · | tweet ↗ |
| 2026-06-22 | @PersimmonTI | +0.50 | WSJ says FDA will reverse rejection; RGNX plans to refile gene-therapy application. | · | tweet ↗ |
| 2026-06-22 | @adamfeuerstein | +0.50 | FDA reverses course on Regenxbio childhood gene therapy after rejection. | · | tweet ↗ |
| 2026-06-22 | @BioStocks | +0.45 | FDA indicated no new subjects required for RGNX confirmatory study, only longer follow-up. | · | tweet ↗ |
| 2026-06-22 | @BioStocks | +0.55 | FDA will reverse rejection of RGNX rare-disease drug; company plans Q3 refiling. | · | tweet ↗ |
| 2026-06-22 | @WSJ | +0.50 | FDA is reversing February rejection of Regenxbio gene therapy. | · | tweet ↗ |
| 2026-06-21 | @InvestmentGuru_ | +0.55 | Long AI healthcare and biotech framework with multiple gene therapy, diagnostics and digital health plays. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.